Bausch Health Companies (DB:BVF) - Stock Price, News & Analysis

BVF Stock Overview

Operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. More details

BVF fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 84.5% below our estimate of its fair value

Earnings are forecast to grow 218.28% per year

Earnings have grown 34.6% per year over the past 5 years

Risk Analysis

Negative shareholders equity

Bausch Health Companies Inc. Competitors

Dermapharm Holding

XTRA:DMP

€2.0b

Bayer

XTRA:BAYN

€18.8b

PharmaSGP Holding

XTRA:PSG

€309.3m

Merck KGaA

XTRA:MRK

€61.7b

Price History & Performance

Summary of all time highs, changes and price drops for Bausch Health Companies
Historical stock prices
Current Share Price	US$8.66
52 Week High	US$9.82
52 Week Low	US$4.69
Beta	0.74
11 Month Change	17.12%
3 Month Change	68.01%
1 Year Change	n/a
33 Year Change	-58.46%
5 Year Change	-66.49%
Change since IPO	-4.21%

Recent updates

Shareholder Returns

	BVF	DE Pharmaceuticals	DE Market
7D	0%	1.6%	1.1%
1Y	n/a	-19.0%	7.2%

Return vs Industry: Insufficient data to determine how BVF performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how BVF performed against the German Market.

Price Volatility

Is BVF's price volatile compared to industry and market?
BVF volatility
BVF Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine BVF's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	20,270	Tom Appio	www.bauschhealth.com

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.

Bausch Health Companies Inc. Fundamentals Summary

How do Bausch Health Companies's earnings and revenue compare to its market cap?
BVF fundamental statistics
Market cap	€2.83b
Earnings (TTM)	-€168.48m
Revenue (TTM)	€8.97b

0.3x

P/S Ratio

-16.8x

P/E Ratio

Is BVF overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BVF income statement (TTM)
Revenue	US$9.47b
Cost of Revenue	US$2.76b
Gross Profit	US$6.71b
Other Expenses	US$6.89b
Earnings	-US$178.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.48
Gross Margin	70.87%
Net Profit Margin	-1.88%
Debt/Equity Ratio	-8,887.2%

How did BVF perform over the long term?

See historical performance and comparison

BVF Stock Overview

Rewards

Risk Analysis

Bausch Health Companies Inc. Competitors

XTRA:DMP

€2.0b

XTRA:BAYN

€18.8b

XTRA:PSG

€309.3m

XTRA:MRK

€61.7b

Price History & Performance

Recent News & Updates

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.03 loss in 3Q 2023)

Forecast breakeven date moved forward to 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Recent updates

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.03 loss in 3Q 2023)

Forecast breakeven date moved forward to 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Second quarter 2024 earnings released: EPS: US$0.027 (vs US$0.071 in 2Q 2023)

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.55 loss in 1Q 2023)

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Full year 2023 earnings released: US$1.62 loss per share (vs US$0.62 loss in FY 2022)

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

No longer forecast to breakeven

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

No longer forecast to breakeven

Third quarter 2023 earnings released: US$1.04 loss per share (vs US$1.10 profit in 3Q 2022)

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

No longer forecast to breakeven

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.19 loss in 1Q 2022)

Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: US$0.62 loss per share (vs US$2.64 loss in FY 2021)

Investor sentiment improves as stock rises 23%

Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improved over the past week

Bausch Health Companies Inc. Announces Availability of ARAZLOTM

Third quarter 2022 earnings released: EPS: US$1.10 (vs US$0.52 in 3Q 2021)

Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022

Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022

Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada

Insider recently sold €708k worth of stock

Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)

Investor sentiment improved over the past week

Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin

Investor sentiment improved over the past week

Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit